Professional Documents
Culture Documents
1 Vitamin D A Pleiotropic Hormone PDF
1 Vitamin D A Pleiotropic Hormone PDF
org
& 2010 International Society of Nephrology
1,25(OH)2D3-induced intestinal Ca2 þ absorption.4 Surpris- necessary for timely vascular invasion and osteoclastogenesis
ingly, inactivation of TRPV6 and calbindin D9k does not during bone growth and that this pathway is required for
impair intestinal Ca2 þ absorption when dietary calcium proper endocrine action of bone in phosphate homeostasis.
intake is normal, indicating the contribution of compensa- The function of VDR in osteoblasts seems to be modu-
tory proteins. Nevertheless, TRPV6 becomes critical for Ca2 þ lated as a function of the differentiation stage of the cells.
absorption when dietary calcium intake is low, as evidenced Indeed, VDR activation in pre-osteoblasts suppresses bone
by the impaired intestinal Ca2 þ absorption in TRPV6 null formation as calvarial osteoblasts from VDR null mice
mice on a low calcium diet.5,6 A possible explanation for the displayed enhanced osteogenesis in vitro,11 whereas the
lack of effect is that 1,25(OH)2D3 action not only affects expression of a VDR transgene in mature osteoblasts results
transcellular but also paracellular Ca2 þ transport. Indeed, in increased bone mass.12
1,25(OH)2D3 may regulate tight junction permeability in the Selective deletion of VDR from the parathyroid glands
intestine by modifying the expression of several tight junc- causes a doubling of PTH levels and increased bone turnover
tion proteins, including claudin-2 and claudin-12 and hereby without overall negative effects on bone.13 This indicates that
promoting Ca2 þ absorption.7 As mentioned, 1,25(OH)2D3 the calcium-sensing parathyroid gland is a direct target for
promotes renal Ca2 þ reabsorption that correlates with vitamin D action and thus may contribute to the secondary
increased expression of TRPV5 and calbindin D9k. In contrast hyperparathyroidism in chronic renal failure.
to the limited contribution of TRPV6 to intestinal Ca2 þ Taken together, the major function of 1,25(OH)2D3/VDR
absorption, TRPV5 is definitely critical for renal Ca2 þ signaling is to guarantee normal serum Ca2 þ levels, but this
reabsorption. Indeed, TRPV5 null mice display a profound pathway also directly affects the homeostasis and endocrine
Ca2 þ wasting with compensatory increased intestinal Ca2 þ function of bone.
absorption, likely due to high 1,25(OH)2D3 serum levels, and
normocalcemia as a result.8 VITAMIN D AND CANCER
If the major action of 1,25(OH)2D3 is to keep serum Ca2 þ Several large-scale epidemiological studies have shown an
levels within restricted limits, the question can be raised inverse correlation between exposure to sunlight (the major
whether the sole action of 1,25(OH)2D3 on bone is to source of vitamin D) or vitamin D intake and risk of
diminish changes in the serum Ca2 þ concentrations by colorectal, breast, and prostate cancer. However, the fact that
increased bone resorption or whether there is also a direct people in sunny Southern Europe have a lower vitamin D
(positive) effect of 1,25(OH)2D3 on bone homeostasis. status than those in Northern Europe indicates that sun
Indeed, 1,25(OH)2D3 can stimulate bone resorption by exposure and diet are not such good indicators for the
increasing the expression of osteoclastogenic factors (for vitamin D status.14 Moreover, the vitamin D content in food
example, receptor activator of nuclear factor kB ligand) in is highly variable. Therefore, prospective studies using serum
osteoblasts. There is, however, increasing evidence that 25(OH)D3 levels to assess vitamin D status are more accurate
1,25(OH)2D3-mediated signaling has a defined, albeit non- to study the relationship between 25(OH)D3 status and
essential function in regulating the activity of chondrocytes cancer incidence. A recent meta-analysis of the association
and osteoblasts during endochondral bone formation and between serum 25(OH)D3 and colorectal cancer risk15
bone homeostasis. A first indication is the observation that supports the conclusion that lower serum 25(OH)D3 levels
aberrant growth plate development in VDR-deficient mice are inversely associated with colorectal cancer and confirmed
appears before the onset of hypocalcemia and that a high another meta-analysis,16 which reported that a 51% lower
calcium diet corrected all aspects of the phenotype of incidence of colorectal cancer was associated with the highest
CYP27B1-deficient mice, except long bone growth.1 Genetic serum 25(OH)D3 quintile (82 nmol/l) compared to the
evidence is provided by the phenotype of mice lacking VDR lowest quintile (p30 nmol/l). The association between breast
expression in chondrocytes.9 These mice display a normal cancer risk and 25(OH)D3 status has been studied among
growth plate, but develop a transient phenotype of increased others in the United States17 as well as in Europe.18 The UK
bone volume postnatally, likely due to decreased expression study showed that women with 25(OH)D3 levels o50 nmol/l
of the angiogenic factor vascular endothelial growth factor have an odds ratio of 3.54 for breast cancer risk compared
and the osteoclastogenic factor receptor activator of nuclear with women with levels 450 nmol/l. However, other
factor kB ligand in chondrocytes. In addition, VDR signaling epidemiological studies failed to show an inverse correlation
in chondrocytes increases, by an unidentified mechanism, the between 25(OH)D3 circulating levels and breast cancer
expression of the phosphaturic factor FGF23 in osteoblasts. incidence. Similarly the association between 25(OH)D3 status
FGF23 signals to the kidney where it reduces phosphate and prostate cancer19 is less clear than for colorectal cancer.
reabsorption and CYP27B1 activity. Although not completely Moreover, the association between overall cancer outcome
identical, most of these effects are also observed when and 25(OH)D3 remains ambiguous. In the large WHI,
CYP27B1 is deleted in chondrocytes, supporting a physio- combined treatment of vitamin D3 (400 IU per day) and
logical function for an autocrine/paracrine vitamin D calcium did not decrease colon cancer risk,20 whereas in a
pathway in developing chondrocytes.10 These data indicate much smaller randomized control trial 1100 IU per day of
that 1,25(OH)2D3-mediated signaling in chondrocytes is vitamin D3 along with calcium decreased the overall cancer
These immunomodulatory effects of 1,25(OH)2D3 can A poor vitamin D status is linked with all major diseases
clearly be observed in vivo in circumstances of vitamin D causing the majority of human morbidity, such as cancer,
deficiency both in humans and in animal models of human immune diseases, metabolic syndrome, hypertension, and
disease. Decreased antibacterial and antiviral defenses are cardiovascular risk factors. Correction of vitamin D defi-
obvious in vitamin D deficiency and restoration of the ciency or insufficiency usually requires vitamin D supple-
vitamin D-sufficient state restores immune responses. mentation as higher exposure to UVB light carries a risk for
Correlations between the existence of vitamin D deficiency skin damage and carcinogenesis and as naturally vitamin
and higher prevalence of autoimmunity have been described D-rich food is scarce. In Europe, the vitamin D3 is preferred
for many diseases and in different populations. Indeed, many whereas vitamin D2 is widely added to food or used as
epidemiological studies have shown a clear association supplement in North America. The natural D3 compound is
between low vitamin D status and autoimmune diseases, probably slightly more potent than vitamin D2 especially
such as type 1 diabetes,34 multiple sclerosis,35,36 and when given intermittently. The optimal daily dosage is highly
inflammatory bowel disease. Preclinical animal models have debated but most randomized controlled trials used
confirmed that vitamin D deficiency especially early in life 600–1000 IU of vitamin D3 per day and such therapy was
enhances such autoimmune diseases. Prospective interven- found to decrease the risk of fractures and falls in the elderly.
tion studies with either vitamin D or selective VDR The serum 25(OH)D concentration should certainly exceed
modulators are, however, needed to evaluate their therapeu- 20 ng/ml (or 50 nmol/l) and probably even 30 ng/ml
tic potential. (80 nmol/l) in patients with impaired renal function. As the
mean level of 25(OH)D around the world is only about
CARDIOVASCULAR AND METABOLIC ACTIONS 20 ng/ml41 and not higher than 30 ng/ml in the US NHANES
Vitamin D-deficient rats or mice with deletion of VDR or IV participants,42 it can be easily assumed that a very large
1a-hydroxylase develop high renin hypertension with part of the human population and thus even billions of
ultimately cardiac hypertrophy. Selective VDR deficiency in people is at least mildly vitamin D deficient.
cardiac myocytes can reproduce the effects.37 In normo- Patients with chronic renal failure have a greater than
tensive and hypertensive Caucasian, Hispanic, or African normal risk for bone diseases, cancer, immune disorders,
Americans lower serum 25(OH)D levels are associated with as well as increased cardiovascular mortality. They also
higher blood pressure.38 Moreover, in normotensive and have impaired production of 1,25(OH)2D3 and frequently
hypertensive patients blood pressure is inversely correlated combine this with 25(OH)D3 deficiency. A number of
with plasma 1,25(OH)2D and renin concentrations.1 How- observational studies have shown that treatment of hemo-
ever, low 25(OH)D levels are also associated with nearly all dialysis patients with active vitamin D analogs decreases
aspects of the metabolic syndrome, such as obesity, insulin (cardiovascular) mortality. The overall contribution of
resistance, type 2 diabetes. The fat–vitamin D axis is further combined impaired 25(OH)D3–1,25(OH)2D3 status on
underlined by lower fat mass and resistance to diet-induced morbidity and mortality in patients with chronic renal
obesity in VDR null mice and a negative effect of the major failure may be substantial but needs further randomized
fat cell hormone, leptin, on renal 1a-hydroxylase activity. control trials.
However, there are only very small scale intervention studies
using vitamin D or its active hormone on blood pressure or DISCLOSURE
AV, GC, and CM declared no competing interests. RB received
other aspects of the metabolic syndrome.39,40
consultancy fees (Lilly, Indianapolis, IN, USA, Tibotec, Mechelen,
Belgium, BioXell, Segrate, Italy) and lecture fees (Merck & Co.,
CLINICAL PERSPECTIVES Whitehouse Station, NJ, USA, Amgen, Thousand Oaks, CA, USA) and
The major function of 1,25(OH)2D3/VDR signaling is to has intellectual property rights on a university patent on vitamin D
control the calcium and bone homeostasis. Data obtained in analogs licensed to Hybrigenics, France.
animal models of vitamin D deficiency and resistance are
generally perfectly in line with observations in rare patients ACKNOWLEDGMENTS
We thank Femke Baeke and Lieve Verlinden for the creation of the
with such human diseases. The combined presence of figures and Evelyne van Etten for editorial assitance. CM is a clinical
25(OH)D3-1a-hydroxylase as well as VDR in several non- researcher for the Fund for Scientific Research (FWO-Vlaanderen). The
classical tissues introduced the concept of a paracrine/ work in the author’s laboratories was supported by FWO Vlaanderen
autocrine function for 1,25(OH)2D3 outside the calcium (FWO G.0587.09, G.0553.06, G.0552.06), the University of Leuven
and bone metabolism. Moreover, the fact that 1,25(OH)2D3 (GOA/04/10, EF/05/007), and Belgium Program on Interuniversity
Poles of Attraction (P6/34).
was found to be capable of regulating cell differentiation and
proliferation of normal (immune) cells and malignant cells
REFERENCES
created new perspectives for this molecule. The extensive 1. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human
studies in cells, tissues, and whole animals with modified health: lessons from vitamin D receptor null mice. Endocr Rev 2008;
29: 726–776.
vitamin D action have generated clear hypothesis to evaluate 2. Xue Y, Fleet JC. Intestinal vitamin D receptor is required for normal
the function of vitamin D (deficiency) on a whole spectrum calcium and bone metabolism in mice. Gastroenterology 2009; 136:
of human diseases. 1317–1327.
3. Lieben L, Masuyama R, Moermans K et al. Intestinal-Specific Vitamin D 23. Verlinden L, Eelen G, Van HR et al. 1alpha,25-Dihydroxyvitamin
receptor null mice maintain normal calcemia but display severe bone D3-induced down-regulation of the checkpoint proteins, Chk1 and
loss. J Bone Miner Res 2008; 23: S104. Claspin, is mediated by the pocket proteins p107 and p130. J Steroid
4. Van Cromphaut SJ, Dewerchin M, Hoenderop JG et al. Duodenal calcium Biochem Mol Biol 2007; 103: 411–415.
absorption in vitamin D receptor-knockout mice: functional and 24. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in
molecular aspects. Proc Natl Acad Sci USA 2001; 98: 13324–13329. cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:
5. Bianco SD, Peng JB, Takanaga H et al. Marked disturbance of calcium 684–700.
homeostasis in mice with targeted disruption of the Trpv6 calcium 25. Medioni J, Deplanque G, Maurina T et al. Dose finding and safety analysis
channel gene. J Bone Miner Res 2007; 22: 274–285. of inecalcitol in combination with a docetaxel-prednisone regimen in
6. Benn BS, Ajibade D, Porta A et al. Active intestinal calcium transport in the hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol 2009;
absence of transient receptor potential vanilloid type 6 and calbindin- 155: 5151.
D9k. Endocrinology 2008; 149: 3196–3205. 26. Lehmann B. The vitamin D3 pathway in human skin and its role for
7. Fujita H, Sugimoto K, Inatomi S et al. Tight junction proteins claudin-2 regulation of biological processes. Photochem Photobiol 2005; 81:
and -12 are critical for vitamin D-dependent Ca2+ absorption between 1246–1251.
enterocytes. Mol Biol Cell 2008; 19: 1912–1921. 27. Baeke F, van Etten E, Gysemans C et al. Vitamin D signaling in
8. Hoenderop JG, van Leeuwen JP, van der Eerden BC et al. Renal Ca2+ immune-mediated disorders: evolving insights and therapeutic
wasting, hyperabsorption, and reduced bone thickness in mice lacking opportunities. Mol Aspects Med 2008; 29: 376–387.
TRPV5. J Clin Invest 2003; 112: 1906–1914. 28. Sigmundsdottir H, Pan J, Debes GF et al. DCs metabolize sunlight-
9. Masuyama R, Stockmans I, Torrekens S et al. Vitamin D receptor in induced vitamin D3 to ‘program’ T cell attraction to the epidermal
chondrocytes promotes osteoclastogenesis and regulates FGF23 chemokine CCL27. Nat Immunol 2007; 8: 285–293.
production in osteoblasts. J Clin Invest 2006; 116: 3150–3159. 29. Szeles L, Keresztes G, Torocsik D et al. 1,25-Dihydroxyvitamin D3 is
10. Naja RP, Dardenne O, Arabian A et al. Chondrocyte-specific modulation of an autonomous regulator of the transcriptional changes leading
CYP27B1 expression supports a role for local synthesis of 1,25- to a tolerogenic dendritic cell phenotype. J Immunol 2009; 182:
dihydroxyvitamin D3 in growth plate development. Endocrinology 2009; 2074–2083.
150: 4024–4032. 30. Adorini L, Penna G. Dendritic cell tolerogenicity: a key mechanism in
11. Sooy K, Sabbagh Y, Demay MB. Osteoblasts lacking the vitamin D immunomodulation by vitamin D receptor agonists. Hum Immunol
receptor display enhanced osteogenic potential in vitro. J Cell Biochem 2009; 70: 345–352.
2005; 94: 81–87. 31. Yu S, Bruce D, Froicu M et al. Failure of T cell homing, reduced CD4/
12. Gardiner EM, Baldock PA, Thomas GP et al. Increased formation and CD8alphaalpha intraepithelial lymphocytes, and inflammation in the
decreased resorption of bone in mice with elevated vitamin D receptor in gut of vitamin D receptor KO mice. Proc Natl Acad Sci USA 2008; 105:
mature cells of the osteoblastic lineage. FASEB J 2000; 14: 1908–1916. 20834–20839.
13. Meir T, Levi R, Lieben L et al. Deletion of the vitamin D receptor 32. Adorini L, Giarratana N, Penna G. Pharmacological induction of
specifically in the parathyroid demonstrates a limited role for the VDR in tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004;
parathyroid physiology. Am J Physiol Renal Physiol 2009; 297: 16: 127–134.
F1192–F1198. 33. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin
14. van der Wielen RP, Lowik MR, van den BH et al. Serum vitamin D concen- D-mediated human antimicrobial response. Science 2006; 311:
trations among elderly people in Europe. Lancet 1995; 346: 207–210. 1770–1773.
15. Yin L, Grandi N, Raum E et al. Meta-analysis: longitudinal studies of serum 34. Mathieu C, Gysemans C, Giulietti A et al. Vitamin D and diabetes.
vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30: Diabetologia 2005; 48: 1247–1257.
113–125. 35. Cantorna MT. Vitamin D and multiple sclerosis: an update. Nutr Rev 2008;
16. Gorham ED, Garland CF, Garland FC et al. Optimal vitamin D status for 66: S135–S138.
colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 36. Munger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels
2007; 32: 210–216. and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.
17. Bertone-Johnson ER, Chen WY, Holick MF et al. Plasma 25-hydroxyvitamin 37. Gardner DG, Glenn D, Nei W et al. Cardiomyocyte-specific vitamin D
D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer receptor gene knockout causes cardiac hypertrophy. Abstract at the
Epidemiol Biomarkers Prev 2005; 14: 1991–1997. 14th workshop on vitamin D, 4–8 October 2009, Brugge, Belgium.
18. Colston KW. Vitamin D and breast cancer risk. Best Pract Res Clin 38. Bouillon R. Vitamin D as potential baseline therapy for blood pressure
Endocrinol Metab 2008; 22: 587–599. control. Am J Hypertens 2009; 22: 816.
19. Travis RC, Crowe FL, Allen NE et al. Serum vitamin D and risk of prostate 39. Schmitz KJ, Skinner HG, Bautista LE et al. Association of 25-hydroxy-
cancer in a case-control analysis nested within the European Prospective vitamin D with blood pressure in predominantly 25-hydroxyvitamin
Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 2009; 169: D deficient Hispanic and African Americans. Am J Hypertens 2009; 22:
1223–1232. 867–870.
20. Wactawski-Wende J, Kotchen JM, Anderson GL et al. Calcium plus vitamin 40. Margolis KL, Ray RM, Van HL et al. Effect of calcium and vitamin D
D supplementation and the risk of colorectal cancer. N Engl J Med 2006; supplementation on blood pressure: the Women’s Health Initiative
354: 684–696. Randomized Trial. Hypertension 2008; 52: 847–855.
21. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium 41. Hagenau T, Vest R, Gissel TN et al. Global vitamin D levels in relation
supplementation reduces cancer risk: results of a randomized trial. to age, gender, skin pigmentation and latitude: an ecologic
Am J Clin Nutr 2007; 85: 1586–1591. meta-regression analysis. Osteoporos Int 2009; 20: 133–140.
22. Wang X, Gocek E, Liu CG et al. MicroRNAs181 regulate the expression of 42. Ginde AA, Liu MC, Camargo Jr CA. Demographic differences and trends
p27Kip1 in human myeloid leukemia cells induced to differentiate by of vitamin D insufficiency in the US population, 1988–2004. Arch Intern
1,25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736–741. Med 2009; 169: 626–632.